

C Robert Horsburgh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/879816/publications.pdf>

Version: 2024-02-01

139
papers

10,097
citations

66343

42
h-index

36028

97
g-index

143
all docs

143
docs citations

143
times ranked

8715
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Mycobacterium avium</i> Complex Infection in the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1991, 324, 1332-1338.	27.0	1,006
2	Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. New England Journal of Medicine, 2011, 365, 2155-2166.	27.0	769
3	Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin. New England Journal of Medicine, 1993, 328, 527-532.	27.0	670
4	Priorities for the Treatment of Latent Tuberculosis Infection in the United States. New England Journal of Medicine, 2004, 350, 2060-2067.	27.0	581
5	Management of latent <i>Mycobacterium tuberculosis</i> infection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, 2015, 46, 1563-1576.	6.7	475
6	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine, the, 2017, 5, 291-360.	10.7	459
7	Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet, The, 2002, 360, 528-534.	13.7	378
8	Risk of Progression to Active Tuberculosis Following Reinfection With Mycobacterium tuberculosis. Clinical Infectious Diseases, 2012, 54, 784-791.	5.8	303
9	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e93-e142.	5.6	282
10	Latent Tuberculosis Infection in the United States. New England Journal of Medicine, 2011, 364, 1441-1448.	27.0	277
11	Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recommendations and Reports, 2020, 69, 1-11.	61.1	262
12	Evaluation of exposure-specific risks from two independent samples: A simulation study. BMC Medical Research Methodology, 2011, 11, 1.	3.1	225
13	Latent TB Infection Treatment Acceptance and Completion in the United States and Canada. Chest, 2010, 137, 401-409.	0.8	197
14	Endothelial Function in HIV-Infected Persons. Clinical Infectious Diseases, 2006, 42, 1325-1332.	5.8	191
15	Management of drug-resistant tuberculosis. Lancet, The, 2019, 394, 953-966.	13.7	186
16	High Rates of Clinical and Subclinical Tuberculosis among HIV-Infected Ambulatory Subjects in Tanzania. Clinical Infectious Diseases, 2005, 40, 1500-1507.	5.8	176
17	Estimated Rate of Reactivation of Latent Tuberculosis Infection in the United States, Overall and by Population Subgroup. American Journal of Epidemiology, 2014, 179, 216-225.	3.4	172
18	The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet, The, 2020, 395, 973-984.	13.7	160

#	ARTICLE	IF	CITATIONS
19	Lack of Weight Gain and Relapse Risk in a Large Tuberculosis Treatment Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 344-348.	5.6	144
20	Priorities for Screening and Treatment of Latent Tuberculosis Infection in the United States. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 590-601.	5.6	139
21	Noninvasive Markers of Liver Fibrosis Are Highly Predictive of Liver-Related Death in a Cohort of HCV-Infected Individuals With and Without HIV Infection. <i>American Journal of Gastroenterology</i> , 2010, 105, 1346-1353.	0.4	134
22	Practice Guidelines for the Treatment of Tuberculosis. <i>Clinical Infectious Diseases</i> , 2000, 31, 633-639.	5.8	130
23	Use of a Population-Based Survey to Describe the Health of Boston Public Housing Residents. <i>American Journal of Public Health</i> , 2008, 98, 85-91.	2.7	126
24	Revisiting Rates of Reactivation Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 420-425.	5.6	124
25	The Scope and Impact of Treatment of Latent Tuberculosis Infection in the United States and Canada. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 927-931.	5.6	103
26	Predicting Non-Completion of Treatment for Latent Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 717-721.	5.6	103
27	HIV Infection Does Not Affect the Performance of Noninvasive Markers of Fibrosis for the Diagnosis of Hepatitis C Virus-Related Liver Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 538-544.	2.1	100
28	Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection. <i>Emerging Infectious Diseases</i> , 2013, 19, 416-424.	4.3	100
29	Environmental Risk Factors for Infection with <i>Mycobacterium avium</i> Complex. <i>American Journal of Epidemiology</i> , 2006, 164, 32-40.	3.4	92
30	Undernutrition and Tuberculosis: Public Health Implications. <i>Journal of Infectious Diseases</i> , 2019, 219, 1356-1363.	4.0	92
31	Hospital Water as a Source of <i>Mycobacterium avium</i> Complex Isolates in Respiratory Specimens. <i>Journal of Infectious Diseases</i> , 2004, 189, 98-104.	4.0	73
32	Health-Related Quality of Life of Patients with HIV Disease: Impact of Hepatitis C Coinfection. <i>Clinical Infectious Diseases</i> , 2004, 38, 572-578.	5.8	73
33	Disseminated <i>Mycobacterium avium</i> Complex Disease among Patients Infected with Human Immunodeficiency Virus, 1985-2000. <i>Clinical Infectious Diseases</i> , 2001, 33, 1938-1943.	5.8	71
34	Diabetes, Glycemic Control, and Risk of Tuberculosis. <i>Diabetes Care</i> , 2011, 34, 2530-2535.	8.6	70
35	Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. <i>Clinical Infectious Diseases</i> , 2018, 66, 376-384.	5.8	62
36	Principles for designing future regimens for multidrug-resistant tuberculosis. <i>Bulletin of the World Health Organization</i> , 2014, 92, 68-74.	3.3	60

#	ARTICLE	IF	CITATIONS
37	Prevention of Tuberculosis in Older Adults in the United States: Obstacles and Opportunities. <i>Clinical Infectious Diseases</i> , 2013, 56, 1240-1247.	5.8	58
38	The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. <i>Drug and Alcohol Dependence</i> , 2009, 101, 101-106.	3.2	57
39	Predictors of failure to complete treatment for latent tuberculosis infection. <i>Journal of Infection</i> , 2007, 54, 262-266.	3.3	54
40	Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model. <i>JAMA Internal Medicine</i> , 2017, 177, 1755.	5.1	53
41	Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies. <i>Lancet Respiratory Medicine</i> , 2019, 7, 544-552.	10.7	52
42	Existing blood transcriptional classifiers accurately discriminate active tuberculosis from latent infection in individuals from south India. <i>Tuberculosis</i> , 2018, 109, 41-51.	1.9	51
43	Pilot study of treatment of Buruli ulcer with rifampin and dapson. <i>International Journal of Infectious Diseases</i> , 2002, 6, 60-65.	3.3	44
44	Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. <i>Aids</i> , 2008, 22, 415-420.	2.2	43
45	Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A phase III study in Tanzania. <i>Vaccine</i> , 2010, 28, 7652-7658.	3.8	38
46	A Century of Tuberculosis Epidemiology in the Northern and Southern Hemisphere: The Differential Impact of Control Interventions. <i>PLoS ONE</i> , 2015, 10, e0135179.	2.5	38
47	Effect of malnutrition on radiographic findings and mycobacterial burden in pulmonary tuberculosis. <i>PLoS ONE</i> , 2019, 14, e0214011.	2.5	33
48	The Global Problem of Multidrug-Resistant Tuberculosis. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 2575.	7.4	32
49	Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. <i>The Lancet Global Health</i> , 2019, 7, e200-e208.	6.3	32
50	Risk of <i>Cryptosporidium parvum</i> Transmission between Hospital Roommates. <i>Clinical Infectious Diseases</i> , 2000, 31, 947-950.	5.8	31
51	Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. <i>American Journal of Transplantation</i> , 2020, 20, 1196-1206.	4.7	31
52	Comorbidities in pulmonary tuberculosis cases in Puducherry and Tamil Nadu, India: Opportunities for intervention. <i>PLoS ONE</i> , 2017, 12, e0183195.	2.5	31
53	Risk Factors for Nonadherence with Pap Testing in HIV-Infected Women. <i>Journal of Women's Health</i> , 2011, 20, 1635-1643.	3.3	30
54	Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. <i>BMC Infectious Diseases</i> , 2018, 18, 488.	2.9	30

#	ARTICLE	IF	CITATIONS
55	Interferon γ Responses to Mycobacterial Antigens Protect against Subsequent HIV-Associated Tuberculosis. <i>Journal of Infectious Diseases</i> , 2010, 202, 1265-1272.	4.0	29
56	DAR-901 vaccine for the prevention of infection with <i>Mycobacterium tuberculosis</i> among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial. <i>Vaccine</i> , 2020, 38, 7239-7245.	3.8	28
57	Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. <i>BMC Infectious Diseases</i> , 2008, 8, 32.	2.9	27
58	Predictors of delayed care seeking for tuberculosis in southern India: an observational study. <i>BMC Infectious Diseases</i> , 2017, 17, 567.	2.9	27
59	Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis [Review article]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 146-152.	1.2	26
60	Detection, survival and infectious potential of <i>Mycobacterium tuberculosis</i> in the environment: a review of the evidence and epidemiological implications. <i>European Respiratory Journal</i> , 2019, 53, 1802302.	6.7	26
61	Human Immunodeficiency Virus Infection in a Rural Community in the United States. <i>American Journal of Epidemiology</i> , 2004, 160, 582-588.	3.4	24
62	Baseline Mycobacterial Immune Responses in HIV-Infected Adults Primed with bacille Calmette-Guérin during Childhood and Entering a Tuberculosis Booster Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2007, 195, 118-123.	4.0	22
63	Interaction of nutritional status and diabetes on active and latent tuberculosis: a cross-sectional analysis. <i>BMC Infectious Diseases</i> , 2019, 19, 627.	2.9	21
64	Risk of Progression to Active Tuberculosis Among Foreign-Born Persons With Latent Tuberculosis. <i>Chest</i> , 2007, 131, 1811-1816.	0.8	20
65	Integration of a participatory research strategy into a rural health survey. <i>Journal of General Internal Medicine</i> , 2003, 18, 586-588.	2.6	19
66	Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
67	History of Incarceration and Gang Involvement Are Associated With Recent Sexually Transmitted Disease/HIV Diagnosis in African American Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 131-134.	2.1	17
68	Relationship Between Hepatitis C Clinical Testing Site and Linkage to Care. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu009.	0.9	17
69	An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 563.	1.6	17
70	Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset. <i>Journal of Hepatology</i> , 2019, 71, 62-70.	3.7	17
71	Comparison of profile and treatment outcomes between elderly and non-elderly tuberculosis patients in Puducherry and Tamil Nadu, South India. <i>PLoS ONE</i> , 2021, 16, e0256773.	2.5	17
72	Effect of Exposure to Injection Drugs or Alcohol on Antigen-Specific Immune Responses in HIV and Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2007, 195, 847-856.	4.0	16

#	ARTICLE	IF	CITATIONS
73	Extensively Drug-Resistant Tuberculosis in Women, KwaZulu-Natal, South Africa. <i>Emerging Infectious Diseases</i> , 2011, 17, 1942-1945.	4.3	16
74	Prevalence and risk factors associated with latent tuberculosis infection among household contacts of smear positive pulmonary tuberculosis patients in South India. <i>Tropical Medicine and International Health</i> , 2021, 26, 1645-1651.	2.3	16
75	Polyantigenic Interferon- γ Responses Are Associated with Protection from TB among HIV-Infected Adults with Childhood BCG Immunization. <i>PLoS ONE</i> , 2011, 6, e22074.	2.5	14
76	Randomized clinical trials to identify optimal antibiotic treatment duration. <i>Trials</i> , 2013, 14, 88.	1.6	14
77	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw266.	0.9	14
78	Effect of Antiretroviral Therapy on Treatment Outcomes in a Prospective Study of Extensively Drug-Resistant Tuberculosis (XDR-TB) HIV Coinfection Treatment in KwaZulu-Natal, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 474-480.	2.1	14
79	Geographic and Seasonal Variation in <i>Mycobacterium avium</i> Bacteremia Among North American Patients With AIDS. <i>American Journal of the Medical Sciences</i> , 1997, 313, 341-345.	1.1	13
80	Factors associated with loss to follow-up in a large tuberculosis treatment trial (TBTC Study 22). <i>Contemporary Clinical Trials</i> , 2007, 28, 288-294.	1.8	12
81	The complexity of diagnosing latent tuberculosis infection in older adults in long-term care facilities. <i>International Journal of Infectious Diseases</i> , 2016, 44, 37-43.	3.3	11
82	Partitioning the risk of tuberculosis transmission in household contact studies. <i>PLoS ONE</i> , 2019, 14, e0223966.	2.5	11
83	Predictors of Loss to Follow-Up among Men with Tuberculosis in Puducherry and Tamil Nadu, India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1050-1056.	1.4	11
84	CD4 Recovery on Antiretroviral Therapy Is Associated With Decreased Progression to Liver Disease Among Hepatitis C Virus-Infected Injecting Drug Users. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv019.	0.9	10
85	Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2077-e2085.	5.8	10
86	Estimating the relative probability of direct transmission between infectious disease patients. <i>International Journal of Epidemiology</i> , 2020, 49, 764-775.	1.9	10
87	Comparing tuberculosis gene signatures in malnourished individuals using the TBSignatureProfiler. <i>BMC Infectious Diseases</i> , 2021, 21, 106.	2.9	10
88	Alcohol and Tobacco Use in a Tuberculosis Treatment Cohort during South Africa's COVID-19 Sales Bans: A Case Series. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5449.	2.6	10
89	Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1142-1144.	5.6	10
90	A Large, Simple Trial of a Tuberculosis Vaccine. <i>Clinical Infectious Diseases</i> , 2000, 30, S213-S216.	5.8	9

#	ARTICLE	IF	CITATIONS
91	Predictors of Active Injection Drug Use in a Cohort of Patients Infected With Hepatitis C Virus. <i>American Journal of Public Health</i> , 2013, 103, 105-111.	2.7	9
92	Editorial Commentary: Treatment for Multidrug-Resistant Tuberculosis: It's Worse Than We Thought!. <i>Clinical Infectious Diseases</i> , 2014, 59, 1064-1065.	5.8	9
93	One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. <i>New England Journal of Medicine</i> , 2019, 381, e23.	27.0	9
94	Trends, Mechanisms, and Racial/Ethnic Differences of Tuberculosis Incidence in the US-Born Population Aged 50 Years or Older in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 1594-1603.	5.8	9
95	Clinical manifestations and epidemiology of adolescent tuberculosis in Ukraine. <i>ERJ Open Research</i> , 2020, 6, 00308-2020.	2.6	9
96	Household food insecurity among patients with pulmonary tuberculosis and its associated factors in South India: a cross-sectional analysis. <i>BMJ Open</i> , 2020, 10, e033798.	1.9	8
97	Primary Transmission of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis among HIV-Infected Persons: What Does the Future Hold in Store?. <i>Journal of Infectious Diseases</i> , 2008, 198, 1577-1578.	4.0	7
98	Encouraging News for Multidrug-resistant Tuberculosis Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1337-1338.	5.6	7
99	Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 598-605.	5.6	7
100	Risk factors for death during treatment in pulmonary tuberculosis patients in South India: A cohort study. <i>Indian Journal of Tuberculosis</i> , 2021, 68, 32-39.	0.7	7
101	Increased mortality associated with treated active tuberculosis in HIV-infected adults in Tanzania. <i>Tuberculosis</i> , 2013, 93, 461-466.	1.9	6
102	Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 405-412.	2.1	6
103	Incidence and Mortality of Extrapulmonary Tuberculosis in Ukraine: Analysis of National Surveillance Data. <i>Clinical Infectious Diseases</i> , 2022, 75, 604-612.	5.8	6
104	Tuberculosis. <i>European Respiratory Review</i> , 2014, 23, 36-39.	7.1	5
105	Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis. <i>PLoS ONE</i> , 2019, 14, e0223308.	2.5	5
106	Antibiotics and fecundability among female pregnancy planners: a prospective cohort study. <i>Human Reproduction</i> , 2021, 36, 2761-2768.	0.9	5
107	Self-reported Engagement in Care among U.S. Residents with Latent Tuberculosis Infection: 2011-2012. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1669-1676.	3.2	5
108	Tuberculosis- Learning the Impact of Nutrition (TB LION): protocol for an interventional study to decrease TB risk in household contacts. <i>BMC Infectious Diseases</i> , 2021, 21, 1058.	2.9	5

#	ARTICLE	IF	CITATIONS
109	Mycobacterium avium Complex. , 2015, , 2832-2843.e3.		5
110	Isolation of Mycobacterium avium from Potable Water in Homes and Institutions of Patients with HIV Infection in Finland and the United States. BioMed Research International, 2015, 2015, 1-3.	1.9	4
111	“People listen more to what actors say”™: A qualitative study of tuberculosis-related knowledge, behaviours, stigma, and potential interventions in Puducherry, India. Global Public Health, 2022, 17, 2898-2910.	2.0	4
112	Attrition from HIV care among youth initiating ART in youth-only clinics compared with general primary healthcare clinics in Khayelitsha, South Africa: a matched propensity score analysis. Journal of the International AIDS Society, 2022, 25, e25854.	3.0	4
113	Testing and treatment for latent tuberculosis infection in people living with HIV and substance dependence: a prospective cohort study. BMJ Open, 2022, 12, e058751.	1.9	4
114	Contribution of Reinfection to Annual Rate of Tuberculosis Infection (ARI) and Incidence of Tuberculosis Disease. Clinical Infectious Diseases, 2023, 76, e965-e972.	5.8	4
115	Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis. Annals of the American Thoracic Society, 2020, 17, 202-211.	3.2	3
116	Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine. Journal of Epidemiology and Global Health, 2019, 9, 56.	2.9	3
117	Predictors of Treatment for Hepatitis C Virus (HCV) Infection in Drug Users. Substance Abuse, 2008, 29, 5-15.	2.3	2
118	Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 413-416.	2.1	2
119	Impact of Choice of Test for Latent Tuberculosis Infection on Treatment Acceptance and Completion. Microbiology Insights, 2018, 11, 117863611881131.	2.0	2
120	MDR-TB in children: back to the basics. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1-2.	1.2	2
121	Evaluation of factors influencing Mycobacterium tuberculosis complex recovery and contamination rates in MGIT960. Indian Journal of Tuberculosis, 2020, 67, 466-471.	0.7	2
122	Severe undernutrition in children affects tuberculin skin test performance in Southern India. PLoS ONE, 2021, 16, e0250304.	2.5	2
123	Accuracy of Timika X-ray scoring system to predict the treatment outcomes among tuberculosis patients in India. Indian Journal of Tuberculosis, 2022, 69, 476-481.	0.7	2
124	Missed Tuberculosis Diagnoses: Analysis of Pediatric Autopsy Data From General Hospitals in Lviv, Ukraine. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 300-302.	1.3	2
125	Overestimation of Coprevalent and Underestimation of Incident Tuberculosis in Close Contacts. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 486-487.	5.6	1
126	Nontuberculous Mycobacteria and Testing for Latent Tuberculosis Infection. Clinical Infectious Diseases, 2018, 67, 1308-1308.	5.8	1

#	ARTICLE	IF	CITATIONS
127	2570. HCV Screening Practices Among Adolescents and Young Adults in a National Sample of Federally Qualified Health Centers in the United States. <i>Open Forum Infectious Diseases</i> , 2018, 5, S74-S74.	0.9	1
128	Has compassionate use ever sunk a drug?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 119-120.	1.2	1
129	“Plus Ça Change” <i>Clinical Infectious Diseases</i> , 2020, 70, 2119-2120.	5.8	1
130	Challenging the management of drug-resistant tuberculosis “ Authors' reply. <i>Lancet, The</i> , 2020, 395, 783-784.	13.7	1
131	Estimation of the generation interval using pairwise relative transmission probabilities. <i>Biostatistics</i> , 2021, , .	1.5	1
132	What Can Genetic Relatedness Tell Us About Risk Factors for Tuberculosis Transmission?. <i>Epidemiology</i> , 2022, 33, 55-64.	2.7	1
133	The Scope and Impact of Treatment of Latent Tuberculosis Infection in the United States and Canada. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 481-481.	5.6	0
134	The Cost-Effectiveness of Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
135	In reply. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 968-968.	1.2	0
136	Increasing Drug Resistance Among Persons With Tuberculosis in Massachusetts, 2009–2018. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa300.	0.9	0
137	Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 305-306.	5.6	0
138	Directly Observed Therapy to Measure Adherence to Tuberculosis Medication in Observational Research: Protocol for a Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e24510.	1.0	0
139	Effect of treatment adherence on the association between sex and unfavourable treatment outcomes among tuberculosis patients in Puducherry, India: a mediation analysis. <i>Journal of Public Health</i> , 0, , .	1.8	0